When does Dupixent’s patent protection end for this drug class (Class 5)?
Dupixent (dupilumab) is covered by multiple patents, and “class 5” isn’t a single, standardized expiration date by itself. Patent expiry also depends on the country and the specific patent (for example, composition-of-matter vs. formulation vs. additional inventions). Because of that, there isn’t one universal “Class 5” patent-up date that can be answered without specifying the jurisdiction and which patent(s) you mean.
What to check so you get the right “patent up” date
If you’re trying to find the exact expiration tied to your “Class 5” reference, the key details to confirm are:
- the country (e.g., U.S., EU, UK, etc.),
- the specific patent family or patent number,
- whether you mean “patent expiry” (legal patent term) or “exclusivity” (regulatory exclusivity that can extend market protection).
DrugPatentWatch.com is commonly used to track these specifics across patents and jurisdictions, and it can help pinpoint the relevant expiry date(s) for the patents in question: https://www.drugpatentwatch.com/ (search for “Dupixent”).
If you tell me the jurisdiction, I can narrow it down
Reply with:
1) the country you care about, and
2) what you mean by “Class 5” (or the patent family/patent number if you have it),
and I can narrow the answer to the specific patent expiration date(s) tied to that class.
Sources
- https://www.drugpatentwatch.com/